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Adjunctive therapy in epilepsy with new antiepileptic 
drugs: is it of any value? 
C.E. SELAI & M.R. TRIMBLE 
Raymond Way Neuropsychiatry Unit, institute of Neurology, Queen Square, London WC1 N 3BG, UK 
A total of 97 patients were recruited into a prospective, follow-up study after they were prescribed an adjunctive antiepileptic 
drug. The patients were followed up over a 6-month period. The interview included questions on Quality of Life, side-effects, 
adverse events and seizure frequency and severity. We operationally defined patients ‘satisfaction’ as (i) still on new drug; (ii) 
experiencing no side-effects (iii) experiencing no adverse vents and (iv) had a greater than 50% reduction in seizures. A total 
of 13 patients (17%) reported being ‘satisfied’ according to our operational definition. 
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INTRODUCTION 
Approximately 70% of patients with epilepsy are well 
controlled on monotherapy with standard AEDs. For 
the remaining 30%, add-on therapy with one of the 
more recently introduced AEDs is considered. In a re- 
cent retrospective audit of patients starting on lamot- 
rigine and vigabatrin, at 6-8 years follow-up, 86% of 
those patients still living were no longer taking these 
add-on drugs’. No prospective audit of the outcome of 
the newer AEDs has been published which takes ac- 
count both of efficacy and quality of life (QOL). We 
report here the results of a comparative survey of the 6- 
month outcome of clobazam, gabapentin, lamotrigine 
and vigabatrin. 
MATERIALS AND METHODS 
A total of 97 patients who were willing to take part 
were offered the choice of a telephone interview at 
home as an alternative to a face-to-face interview, and 
most patients chose this option. The timing of the in- 
terviews was: (i) baseline; (ii) 3 months from baseline; 
and (iii) 6 months from baseline. Our main outcome 
measures were: seizure frequency and seizure severity, 
as assessed by The National Hospital Seizure Severity 
Scale2. Quality of life was assessed by the QOUS3, 
a patient-driven, semi-structured technique, which as- 
sesses 10 areas of QOL in five domains (physical, 
psychological, social, work/economic and cognitive 
functioning/well-being). Side-effects (patients’ subjec- 
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tive complaints, attributed by the patients to the drug), 
serious adverse events, defined as any epilepsy-related 
health event requiring urgent medical attention, and the 
reason for stopping medication were also recorded. Pa- 
tients were deemed ‘satisfied’ if they fulfilled all of the 
following criteria: (i) still on drug at t = 3; (ii) experi- 
encing no side-effects; (iii) had no adverse events and 
(iv) had a greater than 50% reduction in seizures. 
RESULTS 
Of the 97 patients, 78 attended for both follow-up inter- 
views, and 19 patients failed to attend follow-up. Of the 
78 patients, 15 started on vigabatrin, 20 on clobazam, 
26 on lamotrigine and 17 started on gabapentin. Of 
the other 19, three had started on vigabatrin, four on 
clobazam, six on gabapentin, and six on lamotrigine. 
Table 1 shows individual data for the 78 patients at 
6-month follow-up. 
Quality of life (QOL) 
Figure 1 shows the total QOLAS scores at baseline 
and at 6-month follow-up for two sub-groups of pa- 
tients. The group deemed ‘satisfied’ according to our 
operational definition (n = 13) showed a statistically 
significant improvement in QOL, two-tailed paired 
t-tests, t = 6.78, P < 0.0001. The second group 
in Fig. 1, labelled ‘not satisfied’, did not achieve a 
>50% reduction in seizures and were experiencing 
either side-effects and/or adverse events at t = 3. The 
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Vigabatrin Clobazam Lamotrigine Gabapentin Total 
10/15 08/20 16126 10117 44l78 
Table 1: Individual data for patients at g-month follow-up. 
Status at 6 mos 
Still on drug 
Experiencing side-effect@ 07115 03/20 I O/26 06117 26178 
Experienced seriousb adverse events 01115 04120 01126 05/17 IV78 
50% or more reduction in seizures 08/15 06120 10126 07117 31178 
Number of patients ‘satisfied’c 4/15 4120 3126 2i17 13/78 
Did not attend follow-up interview 3 4 6 6 19 
a Side-effects as reported by patients and attributed by them to the add-on therapy. 
b Serious adverse events are epilepsy-related events requiring urgent medical intervention. 
’ Our operational criteria for ‘satisfied’ were: (i) still on drug at I = 3; (ii) experiencing no side-effects; (iii) had no adverse-events and (iv) 
had a greater than 50% reduction in seizures. 
451 
40 40. 
1 
35. 
35. 
30. . 
2.5. 5. 
20. 
15. 
lo- 
5- 
01 
33.85 33.85 
T  
1 
Satis. 
33.9 31.9 
T 
19.69 
Satis. Not satis. Not satis. 
pre- post- pre- post- 
Fig. 1: Total QOLAS scores for the two groups: ‘satisfied’ (n = 13) and ‘unsatisfied’ (!I = 10) at baseline and at 6-months follow-up. 
The error bars show 95% confidence intervals. The pre- and post-scores for the two groups were compared using paired r-tests. 
The scores for the satisfied group were statistically significantly different, I = 6.78, P > 0.0001. 
marginal improvement was not statistically significant, 
t = 0.91, P < 0.384. 
DISCUSSION 
Of the group (n = 78) who were still on the ‘new’ 
drug at 6-month follow-up, only 17% (n = 13) re- 
ported being ‘satisfied’ (according to our operational 
definition) at 6 months, i.e. had improved quality of 
life, 50% seizure reduction and were experiencing no 
side-effects/adverse events. 
CONCLUSIONS 
Our results suggest that only a minority of patients with 
intractable epilepsy derive substantial treatment bene- 
fit from these drugs when given as add-on therapy. The 
pharmaco-economic consequences of this deserve fur- 
ther study. 
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